Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos

InMed Conferences and Events

Upcoming Events

Past Events

Tribe Public Event “Addressing The Increasing Demand For Rare Cannabinoids”

Date: January 6, 2022

Time: 8:00am PT/ 11:00am ET

We are excited to be hosting Tribe Public’s Next Webinar Presentation and Q&A Event which will be held Thursday, January 6, 2022 (8 am PT/ 11 am ET). Our events are approximately 30 minutes in duration.

Eric A. Adams, CEO & President of InMed Pharmaceuticals, SVP, General Manager of BayMedica Shane Johnson, & VP, Commercial Operations Chris Meiering, PhD will co-host a presentation and Q&A event titled “Addressing The Increasing Demand For Rare Cannabinoids”. There will be a 5-10 minute Q&A session at the end of the presentation, so please send your questions for management to Tribe’s email: [email protected]

Register for the event here.

Add to Calendar

Cowen 4th Annual Cannabis Conference

Date: November 29th – December 1st, 2021

Time: 8:00 am

InMed Pharmaceuticals will be attending Cowen’s 4th Annual Cannabis Conference.  The company will be conducting virtual one-on-one meetings.

This three-day conference will comprise topical panel discussions with C-Suite presenters hosted by Cowen Research and Washington Research Group analysts & along with virtual one-on-one meetings.

*Cowen conferences and events are intended for institutional clients and corporate clients of the firm.  They are not open to media or retail investors.

For more information on the conference, visit Cowen’s webpage at https://www.cowen.com/conferences-and-events/4th-annual-cannabis-conference/

Add to Calendar

InMed Pharmaceuticals’ Eric Hsu joins panel discussion at Benzinga Healthcare Small Cap Conference

Date: September 29th, 2021

Time: 11:55am ET

InMed Pharmaceuticals’ Eric Hsu, Senior Vice President of Preclinical Research and Development, will join the panel discussion “Pharmaceutical Cannabinoids and their Impact on Treatments for Complex Diseases”

To learn more about the Benzinga Healthcare Conference and tune into the panel discussion, join here: https://www.benzinga.com/events/small-cap/healthcare/

Add to Calendar

InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021

Date: Friday, September 24, 2021

Time: 8:00 AM Pacific Time, 11:00 AM Eastern Time

InMed Pharmaceuticals will report financial results for the fiscal year ended June 30, 2021, on Friday, September 24, 2021.

US/CANADA Participant Toll-Free Dial-In Number: +1 (855) 605-1745
US/CANADA Participant International Dial-In Number: +1 (914) 987-7959
Conference ID: 9373618
Webcast: https://edge.media-server.com/mmc/p/ny89uo2r
(*Webcast replay available for 90 days)

The Company’s full financial statements and related MD&A for the fiscal year ended June 30, 2021 will be available at www.inmedpharma.com, www.sedar.com and at www.sec.gov on September 24, 2021.

Add to Calendar

InMed and BayMedica Host First Webinar Together

Date: September 16, 2021

Time: 11:00am ET

As announced on September 13, InMed has signed a definitive agreement to acquire BayMedica, a leading commercial manufacturer of rare cannabinoids.

InMed and BayMedica invite you to join a webinar to learn more about this transaction and to hear about InMed’s future developments.

Join InMed’s CEO, Eric A. Adams, and BayMedica’s co-founder, Shane Johnson, for the webinar, hosted by Edison Research, on Thursday September 16, 2021 at 11:00 am ET.

Watch a replay of the webinar here.

Add to Calendar

InMed’s CEO, Eric A. Adams, and Sr VP of Preclinical Research and Development, Dr. Eric Hsu to Present at H.C. Wainwright Ophthalmology Virtual Conference

Date: Tuesday, August 17th, 2021

Meetings: InMed’s management team will also be conducting meetings with institutional investors throughout the conference. To schedule a meeting, please contact your H.C. Wainwright representative or register for the event at HCW Events.

Add to Calendar

InMed’s CEO, Eric A. Adams, to present at BIO Digital 2021 

Date: June 10-11 and 14-18, 2021

Time: Presentation available on-demand at 9am ET.

Presentation details: 
InMed’s presentation will be available on demand to registered attendees during the conference, starting June 10th at 9am ET. InMed’s presentation can be accessed from the BIO Digital website at https://www.bio.org/events/bio-digital/sessions/800498.

To schedule 1×1 meetings with InMed, please do so through the BIO One on One Partnering System.

Add to Calendar

InMed Pharmaceuticals Webinar

Date: April 28th, 2021

Time: 11:00am ET

Presentation Details: In this live webinar, Eric Adams and Bruce Colwill will present an overview of the company’s recent operating and financial activities, followed by a Q&A session.
Register here.

Add to Calendar

InMed’s CEO, Eric A. Adams, to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Date: Monday, September 13th, 2021

Time: 1:00pm ET

Presentation available on demand from the H.C. Wainwright Events Platform: InMed presentation

An archived replay of the presentation will be available on the Company’s website immediately following the conference and will be available for 90 days.

Meetings: InMed’s management team will also be conducting meetings with institutional investors throughout the conference. To schedule a meeting, please contact your H.C. Wainwright representative or register for the event at HCW Events.

Add to Calendar

InMed to Present at Canaccord Genuity’s 5th Annual Global Cannabis Conference 

Date: May 11th, 2021

Time: 2:30-2:55pm ET

Presentation Details: InMed’s President and CEO, Eric A. Adams, will be presenting at Canaccord Genuity’s 5th Annual Global Cannabis Conference, which will be held virtually this year.
Register here.

To schedule a 1×1 meeting, please do so through the conference portal or reach out to [email protected].

Add to Calendar
Load More


INM-755

A cannabinol (CBN) topical cream in Phase 2 clinical trials for epidermolysis bullosa
Learn More

INM-088

A cannabinol (CBN) formulation in preclinical development for the treatment of glaucoma
Learn More
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Neurodegenerative Disease
  • Novel Cannabinoid Analogs

MANUFACTURING

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis
  • Rare Cannabinoid Ingredients

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent